Cue Biopharma Dividend
Dividend criteria checks 0/6
Cue Biopharma does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
Industry average yield | 2.9% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Earnings per share | -US$1.04 |
Dividend yield forecast in 3Y | n/a |
Recent dividend updates
No updates
Recent updates
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money
Apr 16Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?
Dec 30Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?
Aug 11Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug
Oct 04Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt
Sep 23News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat
Aug 26Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates
Aug 10Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%
May 18Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
May 12Cue Biopharma: A First Assessment
May 11Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Mar 19Cue Biopharma: Too Long To Arrive At Topline Trial Data
Feb 23We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth
Nov 04Cue Biopharma doses first patient in trial for CUE-101 in head and neck cancer
Jun 10Companies Like Cue Biopharma (NASDAQ:CUE) Are In A Position To Invest In Growth
Jun 07Cue Biopharma's CUE-101 shows encouraging action in HPV+ head and neck cancer patients
May 10How Many Cue Biopharma, Inc. (NASDAQ:CUE) Shares Did Insiders Buy, In The Last Year?
Mar 21We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate
Feb 22Is Cue Biopharma, Inc. (NASDAQ:CUE) Popular Amongst Insiders?
Jan 27Cue Biopharma: CUE-101's Phase 1 Promising Progress, 1 New IND Expected, Funding Until Q2 2022
Jan 07Reflecting on Cue Biopharma's (NASDAQ:CUE) Share Price Returns Over The Last Year
Dec 25Independent Director Aaron Fletcher Just Bought 3.9% More Shares In Cue Biopharma, Inc. (NASDAQ:CUE)
Nov 29We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate
Nov 24Cue Biopharma (CUE) Investor Presentation - Slideshow
Nov 20Cue Biopharma EPS beats by $0.12, misses on revenue
Nov 17Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if CUE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CUE's dividend payments have been increasing.
Dividend Yield vs Market
Cue Biopharma Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (CUE) | n/a |
Market Bottom 25% (US) | 1.6% |
Market Top 25% (US) | 4.8% |
Industry Average (Biotechs) | 2.9% |
Analyst forecast in 3 Years (CUE) | n/a |
Notable Dividend: Unable to evaluate CUE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CUE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate CUE's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CUE has not reported any payouts.